Multiple Myeloma in Young Patients: Clinical Presentation and Treatment Approach

References

• Bladé J., Kyle R.A., Greipp P.R. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br. J. Haematol. 1996; 93: 345–351
   PubMed Web of Science ®Google Scholar
• Young J.L., Percy C.L., Asire A.J. Surveillance, epidemiology, and end-results. National Cancer Institute. Monograph 57, U.S. Department of Health and Human Services, Bethesda 1981
   Google Scholar
• Bladé J., Kyle R.A., Greipp P.R. Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch. Intern. Med. 1996; 156: 1463–1468
   PubMed Web of Science ®Google Scholar
• Maeda K., Abesamis C.M., Kuhn L.M., Hyun B.H. Multiple myeloma in childhood: report of a case with breast tumors as a presenting manifestation. Am. J. Clin. Pathol 1973; 60: 552–558
   PubMed Web of Science ®Google Scholar
• Clough V., Delamore I.W., Whittaker J.A. Multiple myeloma in a young woman (letter to the editor). Ann. Intern. Med. 1977; 86: 117–118
   PubMed Web of Science ®Google Scholar
• Levin S.R., Spaulding A.G., Wirman J.A. Multiple myeloma. Orbital involvement in a youth. Arch. Ophthalmol 1977; 95: 642–644
   PubMed Web of Science ®Google Scholar
• Bernstein S.C., Perez-Atayde A.R., Weinstein H.J. Multiple myeloma in a child. Cancer 1985; 56: 2143–2147
   PubMed Web of Science ®Google Scholar
• Prematilleke M.N. Multiple myeloma in a child. Ceylon Med. J. 1987; 32: 143–145
   PubMedGoogle Scholar
• Harster G.A., Krause J.R. Multiple myeloma in two young postpartum women. Arch. Pathol. Lab. Med. 1987; 111: 38–42
   PubMed Web of Science ®Google Scholar
• Rapoport A.P., Rowe J.M. Plasma cell dyscrasia in a 15-year-old boy: case report and review of the literature (letter to the editor). Am. J. Med. 1990; 89: 816–818
   PubMed Web of Science ®Google Scholar
• Pajor A., Kelemen E., Mohos Z., Hambach J., Varadi G. Multiple myeloma in pregnancy. Int. J. Gynaecol. Obstet. 1991; 35: 341–342
   PubMed Web of Science ®Google Scholar
• Kaste S.C., Ripps L.G., Pedrosa F., Ribeiro R.C. Multiple myeloma in an adolescent. Pediatr. Radiol 1992; 22: 293–295
   PubMed Web of Science ®Google Scholar
• Grünwald H.W., Rosner F., Kalman A.C. Immunoglobulin-A plasma cell dyscrasia in a young Hispanic man. N. Y. State J. Med. 1993; 93: 146
   PubMedGoogle Scholar
• Badwey T.M., Murphy D.A., Eyster R.L., Cannon M.W. Multiple myeloma in a 25-year-old woman. Clin. Orthop. 1993; 294: 290–293
   PubMedGoogle Scholar
• Ishida T., Dorfman H.D. Plasma cell myeloma in unusually young patients: a report of two cases and review of the literature. Skeletal Radiol. 1995; 24: 47–51
   PubMed Web of Science ®Google Scholar
• Hewell G.M., Alexanian R. Multiple myeloma in young persons. Ann. Intern. Med. 1976; 84: 441–143
   PubMed Web of Science ®Google Scholar
• Lazarus H.M., Kellermeyer R.W., Aikawa M., Herzig R.H. Multiple myeloma in young men. Clinical course and electron microscopic studies of bone marrow plasma cells. Cancer 1980; 46: 1397–1400
   PubMed Web of Science ®Google Scholar
• Bladé J., Lust J.A., Kyle R.A. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J. Clin. Oncol 1994; 12: 2398–2404
   PubMed Web of Science ®Google Scholar
• Karnad A.B., Martin A.W., Koh H.K., Brauer M.J., Novich M., Wright J. Nonsecretory multiple myeloma in a 26-year-old man with acquired immunodeficiency syndrome, presenting with multiple extramedullary plasmacytomas and osteolytic bone disease. Am. J. Hematol 1989; 32: 305–310
   PubMed Web of Science ®Google Scholar
• Voelkerding K.V., Sandhaus L.M., Kim H.C., Wilson J., Chittenden T., Levine A.J., Raska K., Jr. Plasma cell malignancy in the acquired immune deficiency syndrome: association with Epstein-Barr virus. Am. J. Clin. Pathol 1989; 92: 222–228
   PubMed Web of Science ®Google Scholar
• Gold J.E., Schwam L., Castella A., Pike S.B., Opfell R., Zalusky R. Malignant plasma cell tumors in human immunodeficiency virus-infected patients. Cancer 1990; 66: 363–368
   PubMed Web of Science ®Google Scholar
• Kumar S., Kumar D., Schnadig V.J., Selvanayagam P., Slaughter D.P. Plasma cell myeloma in patients who are HIV-positive. Am. J. Clin. Pathol 1994; 102: 633–639
   Web of Science ®Google Scholar
• Konrad R.J., Kricka L.J., Goodman D.B., Goldman J., Silberstein L.E. Myeloma-associated paraprotein directed against the HIV-1 p24 antigen in an HIV-1-seropositive patient. N. Engl J. Med. 1993; 328: 1817–1819
   PubMed Web of Science ®Google Scholar
• Lefrère J.J., Debbia M., Lambin P. Prospective follow-up of monoclonal gammopathies in HIV-infected individuals. Br. J. Haematol 1993; 84: 151–155
   PubMed Web of Science ®Google Scholar
• Strand W.R., Banks P.M., Kyle R.A. Anaplastic plasma cell myeloma and immunoblastic lymphoma. Clinical, pathologic, and immunologic comparison. Am. J. Med. 1984; 76: 861–867
   PubMed Web of Science ®Google Scholar
• Salmon S.E., Tesh D., Crowley J., Saeed S., Finley P., Milder M.S., Hutchins L.F., Coltman C.A., Jr., Bonnet J.D., Cheson B., Knost J.A., Samhouri A., Beckord J., Stock-Novack D. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J. Clin. Oncol 1990; 8: 1575–1584
   PubMed Web of Science ®Google Scholar
• MacLennan I.C.M., Chapman C., Dunn J., Kelly K., for the Medical Research Council Working Party for Leukaemia in Adults. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. Lancet 1992; 339: 200–205
   PubMed Web of Science ®Google Scholar
• Bladé J., San Miguel J.F., Alcalá A., Maldonado J., Sanz M.A., García-Conde J., Mora M.J., Alonso C., Besalduch J., Zubizarreta A., Besses C., González-Brito G., Hernández-Martín J., Fernández-Calvo J., Rubio D., Ortega F., Jiménez R., Colominas P., Faura M.V., Font L., Tortosa J., Domingo A., Fontanillas M., Rozman C., Estapé J. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J. Clin. Oncol. 1993; 11: 1165–1171
   PubMed Web of Science ®Google Scholar
• Oken M.M. Standard treatment of multiple myeloma. Mayo Clin. Proc. 1994; 69: 781–786
   PubMed Web of Science ®Google Scholar
• Boccadoro M., Marmont F., Tribalto M., Avvisati G., Andriani A., Barbui T., Cantonetti M., Carotenuto M., Comotti B., Dammacco F., Frieri R., Gallamini A., Gallone G., Giovangrossi P., Grignani F., Lauta V.M., Liberati M., Musto P., Noretto G., Petrucci M.T., Resegotti L., Piled A., Mandelli F. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J. Clin. Oncol. 1991; 9: 444–448
   PubMed Web of Science ®Google Scholar
• Bergsagel D.E. Chemotherapy of myeloma. Myeloma. Biology and Management, J.S. Malpas, D.E. Bergsagel, R.A. Kyle. Oxford University Press, Oxford 1995; 273–306
   Google Scholar
• Buckman R., Cuzick J., Galton D.A. Long-term survival in myelomatosis. A report to the MRC working party on leukaemia in adults. Br. J. Haematol. 1982; 52: 589–599
   PubMed Web of Science ®Google Scholar
• Kyle R.A. Long-term survival in multiple myeloma. N. Engl. J. Med. 1983; 308: 314–316
   PubMed Web of Science ®Google Scholar
• Alexanian R. Ten-year survival in multiple myeloma. Arch. Intern. Med. 1985; 145: 2073–2074
   PubMed Web of Science ®Google Scholar
• Dutcher J.P., Wiernik P.H. Long-term survival of a patient with multiple myeloma—a cure? A case report. Cancer 1984; 53: 2069–2072
   PubMed Web of Science ®Google Scholar
• Kyle R.A. IgD multiple myeloma: a cure at 21 years. Am. J. Hematol. 1988; 29: 41–43
   PubMed Web of Science ®Google Scholar
• Bensinger W.I., Demirer T., Buckner C.D., Appelbaum F.R., Storb R., Lilleby K., Weiden P., Bluming A.Z., Fefer A. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant. 1996; 18: 527–531
   PubMed Web of Science ®Google Scholar
• Bensinger W.I., Buckner C.D., Anasetti C., Clift R., Storb R., Barnett T., Chauncey T., Shulman H., Appelbaum F.R. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787–2793
   PubMed Web of Science ®Google Scholar
• Gahrton G., Tura S., Ljungman P., Bladé J., Cavo M., De Laurenzi A., Fajon T., Gratwohl A., Michallet M., Nikoskelainen J., Pearce R., Reiffers J., Samson D., Schattenberg A., Verdonck L., Vernant J.-P., Volin L., for the European Group for Blood and Marrow Transplantation. An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. Stem Cells 1995; 13(Suppl 2)122–125
   PubMedGoogle Scholar
• Tricot G., Vesole D.H., Jagannath S., Hilton J., Munshi N., Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 1996; 87: 1196–1198
   PubMed Web of Science ®Google Scholar
• Verdonck L.F., Lokhorst H.M., Dekker A.W., Nieuwenhuis H.K., Petersen E.J. Graft-versus-myeloma effect in two cases. Lancet 1996; 347: 800–801
   PubMed Web of Science ®Google Scholar
• Aschan J., Lönnqvist B., Ringdén O., Kumlien G., Gahrton G. Graft-versus-myeloma effect (letter to the editor). Lancet 1996; 348: 346
   PubMed Web of Science ®Google Scholar
• Gahrton G., Tura S., Ljungman P., Belanger C., Brandt L., Cavo M., Facon T., Granena A., Gore M., Gratwohl A., Löwenberg B., Nikoskelainen J., Reiffers J.J., Samson D., Verdonck L., Volin L., for the European Group for Bone Marrow Transplantation. Allogeneic bone marrow transplantation in multiple myeloma. N. Engl. J. Med. 1991; 325: 1267–1273
   PubMed Web of Science ®Google Scholar
• Gahrton G., Tura S., Ljungman P., Bladé J., Brandt L., Cavo M., Facon T., Gratwohl A., Hagenbeek A., Jacobs P., de Laurenzi A., Van Lint M., Michallet M., Nikoskelainen J., Reiffers J., Samson D., Verdonck L., de Witte T., Volin L. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J. Clin. Oncol. 1995; 13: 1312–1322
   PubMed Web of Science ®Google Scholar
• Bird J.M., Russell N.H., Samson D. Minimal residual disease after bone marrow transplantation for multiple myeloma: evidence for cure in long-term survivors. Bone Marrow Transplant. 1993; 12: 651–654
   PubMed Web of Science ®Google Scholar
• Vesole D.H., Tricot G., Jagannath S., Desikan K.R., Siegel D., Bracy D., Miller L., Cheson B., Crowley J., Barlogie B. Autotransplants in multiple myeloma: what have we learned?. Blood 1996; 88: 838–847
   PubMed Web of Science ®Google Scholar
• Bensinger W.I., Clift R., Martin P., Appelbaum F.R., Demirer T., Gooley T., Lilleby K., Rowley S., Sanders J., Storb R., Buckner C.D. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: a retrospective comparison with marrow transplantation. Blood 1996; 88: 2794–2800
   PubMed Web of Science ®Google Scholar
• Goldman J. Peripheral blood stem cells for allografting (editorial). Blood 1995; 85: 1413–1415
   PubMed Web of Science ®Google Scholar
• Link H., Arseniev L., Bähre O., Kadar J.G., Diedrich H., Poliwoda H. Transplantation of allogeneic CD34+ blood cells. Blood 1996; 87: 4903–4909
   PubMed Web of Science ®Google Scholar
• Urbano-Ispizua A., Rozman C., Martínez C., Marín P., Briones J., Rovira M., Féliz P., Viguria M.C., Merino A., Sierra J., Mazzara R., Carreras E., Montserrat E. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. Blood 1997; 89: 3967–3973
   PubMed Web of Science ®Google Scholar
• Kwak L.W., Taub D.D., Duffey P.L., Bensinger W.I., Bryant E.M., Reynolds C.W., Longo D.L. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995; 345: 1016–1020
   PubMed Web of Science ®Google Scholar
• Munshi N.C., Govindarajan R., Drake R., Ding L.M., Iyer R., Saylors R., Kornbluth J., Marcus S., Chiang Y., Ennist D., Kwak L., Reynolds C., Tricot G., Barlogie B. Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir. Blood 1997; 89: 1334–1340
   PubMed Web of Science ®Google Scholar
• Björkstrand B., Ljungman P., Svenson H., Hermans J., Alegre A., Apperley J., Bladé J., Carlson K., Cavo M., Ferrant A., Goldstone A.H., de Laurenzi A., Majolino I., Marcus R., Prentice H.G., Remes K., Samson D., Sureda A., Verdonck L.F., Volin L., Gahrton G. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711–4718
   PubMed Web of Science ®Google Scholar
• Barlogie B., Alexanian R., Dicke K.A., Zagars G., Spitzer G., Jagannath S., Horwitz L. High-dose chemora-diotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869–872
   PubMed Web of Science ®Google Scholar
• Vesole D.H., Barlogie B., Jagannath S., Cheson B., Tricot G., Alexanian R., Crowley J. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950–956
   PubMed Web of Science ®Google Scholar
• Anderson K.C. Who benefits from high-dose therapy for multiple myeloma? (Editorial). J. Clin. Oncol. 1995; 13: 1291–1296
   PubMed Web of Science ®Google Scholar
• Alexanian R., Dimopoulos M.A., Hester J., Delasalle K., Champlin R. Early myeloablative therapy for multiple myeloma. Blood 1994; 84: 4278–4282
   PubMed Web of Science ®Google Scholar
• Fermand J.P., Levy Y., Gerota J., Benbunan M., Cosset J.M., Castaigne S., Seligmann M., Brouet J.-C. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989; 73: 20–23
   PubMed Web of Science ®Google Scholar
• Attal M., Huguet F., Schlaifer D., Payen C., Laroche M., Fournie B., Mazieres B., Pris J., Laurent G. Intensive combined therapy for previously untreated aggressive myeloma. Blood 1992; 79: 1130–1136
   PubMed Web of Science ®Google Scholar
• Harousseau J.L., Milpied N., Laporte J.P., Collombat P., Facon T., Tigaud J.D., Casassus P., Guilhot F., Ifrah N., Gandhour C. Double-intensive therapy in high-risk multiple myeloma. Blood 1992; 79: 2827–2833
   PubMed Web of Science ®Google Scholar
• Anderson K.C., Andersen J., Soiffer R., Freedman A.S., Rabinowe S.N., Robertson M.J., Spector N., Blake K., Murray C., Freeman A., Coral F., Marcus K.C., Mauch P., Nadler L.M., Ritz J. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood 1993; 82: 2568–2576
   PubMed Web of Science ®Google Scholar
• Gianni A.M., Tarella C., Bregni M., Siena S., Lombardi F., Gandola L., Caracciolo D., Stern A., Bonadonna G., Boccadoro M., Pileri A. High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma. J. Clin. Oncol. 1994; 12: 503–509
   PubMed Web of Science ®Google Scholar
• Dimopoulos M.A., Alexanian R., Przepiorka D., Hester J., Andersson B., Giralt S., Mehra R., van Besien K., Delasalle K.B., Reading C., Deisseroth A.B., Champlin R.E. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 1993; 82: 2324–2328
   PubMed Web of Science ®Google Scholar
• Jagannath S., Vesole D.H., Glenn L., Crowley J., Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80: 1666–1672
   PubMed Web of Science ®Google Scholar
• Cunningham D., Paz-Ares L., Milan S., Powles R., Nicolson M., Hickish T., Selby P., Treleavan J., Viner C., Malpas J., Slevin M., Findlay M., Raymond J., Gore M.E. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J. Clin. Oncol. 1994; 12: 759–763
   PubMed Web of Science ®Google Scholar
• Marit G., Faberes C., Pico J.L., Boiron J.M., Bourhis J.H., Brault P., Bernard P., Foures C., Cony-Makhoul P., Puntous M., Vezon G., Broustet A., Girault D., Reiffers J. Autologous peripheral-blood progenitor-cell support following high-dose chemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma. J. Clin. Oncol. 1996; 14: 1306–1313
   PubMed Web of Science ®Google Scholar
• Attal M., Harousseau J.-L., Stoppa A.-M., Sotto J.-J., Fuzibet J.-G., Rossi J.-F., Casassus P., Maisonneuve H., Facon T., Ifrah N., Payen C., Bataille R., for the Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med. 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Fermand J.P., Ravaud P., Chevret S., Divine M., Leblond V., Belanger C., Dreyfus F., Troussard X., Brechignac S., Mariette X., Brouet J.C. Early versus late high dose therapy (HDT) and autologous peripheral blood stem cell (PBSC) transplantation in multiple myeloma (MM): results of a prospective randomized trial (abstract). Blood 1996; 88(Suppl 1)685a
   Google Scholar
• Bladé J., San Miguel J.F., Fontanillas M., Alcalá A., Maldonado J., García-Conde J., Conde E., González-Brito G., Moro M.J., Escudero M.L., Trujillo J., Pascual A., Rozman C., Estapé J., Montserrat E. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J. Clin. Oncol. 1996; 14: 2167–2173
   PubMed Web of Science ®Google Scholar
• Harousseau J.-L., Attal M., Divine M., Marit G., Leblond V., Stoppa A.-M., Bourhis J.-H., Caillot D., Boasson M., Abgrall J.-F., Facon T., Linassier C., Cahn J.-Y., Lamy T., Troussard X., Gratecos N., Pignon B., Auzanneau G., Bataille R. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French Registry on autologous transplantation in multiple myeloma. Blood 1995; 85: 3077–3085
   PubMed Web of Science ®Google Scholar